Scalper1 News
Biotech Dynavax Technologies (DVAX) soared Thursday, even as the market overall crashed, after its hepatitis B vaccine beat GlaxoSmithKline’s (GSK) standard product in a late-stage clinical trial. Dynavax said that its vaccine, Hepislav-B, showed a 95.4% rate of peak seroprotection, in contrast with only 81.3% for Glaxo’s Engerix-B. Dynavax focused especially on patients with diabetes mellitus, who don’t respond well to current vaccines and Scalper1 News
Scalper1 News